Esperion Therapeutics Inc

Financials

Cash from operating activities -34.95 M-22.63 M-31.42 M-4.29 M45.24 M -13.09 M Cash from investing activities 00000 0 Cash from financing activities 35 M-7.5 M2.85 M10.67 M30.16 M 36.18 M Free cash flow -34.95 M-22.63 M-31.42 M-4.29 M45.24 M -13.09 M

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

ESPR

Financials

Esperion Therapeutics Inc

Haberler

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Esperion, Japonya telif haklarını 50 milyon dolara sattı

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

BofA, Esperion Therapeutics hissesi için düşük performans notunu korudu

BofA reiterates Esperion Therapeutics stock Underperform rating

Bempedoik asit kolesterol için üst düzey kılavuz önerisi aldı

Bempedoic acid gains top-level guideline recommendations for cholesterol

Citizens, Esperion Therapeutics için hedef fiyatı yükseltti

Citizens raises Esperion Therapeutics price target on drug growth

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

H.C. Wainwright, Esperion hissesi için Al tavsiyesini yineledi

H.C. Wainwright reiterates Buy on Esperion stock, $16 target